Donor T cells for CAR T cell therapy

Adoptive cell therapy using patient-derived chimeric receptor antigen (CAR) T cells redirected against tumor cells has shown remarkable success in treating hematologic cancers. However, wider accessibility of cellular therapies for all patients is needed. Manufacture of patient-derived CAR T cells i...

Full description

Saved in:
Bibliographic Details
Published in:Biomarker research 2022-04, Vol.10 (1), p.14-14, Article 14
Main Authors: Tang, Tiffany C Y, Xu, Ning, Nordon, Robert, Haber, Michelle, Micklethwaite, Kenneth, Dolnikov, Alla
Format: Article
Language:English
Subjects:
Adoptive immunotherapy
Antigens
B cells
Cancer
Care and treatment
Cell therapy
Chemotherapy
Clinical trials
Contamination
CRISPR
CRISPR-Cas9
Donor CAR T cells
Genome editing
Genomes
Graft rejection
Graft-versus-host reaction
GVHD
Immunotherapy
Leukemia
Lymphocytes
Lymphocytes T
Lymphoma
Lymphopenia
Patients
Pediatrics
Review
T cell receptors
T cells
TALENs
Toxicity
Tumor cells
Umbilical cord
Vectors (Biology)
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Adoptive cell therapy using patient-derived chimeric receptor antigen (CAR) T cells redirected against tumor cells has shown remarkable success in treating hematologic cancers. However, wider accessibility of cellular therapies for all patients is needed. Manufacture of patient-derived CAR T cells is limited by prolonged lymphopenia in heavily pre-treated patients and risk of contamination with tumor cells when isolating T cells from patient blood rich in malignant blasts. Donor T cells provide a good source of immune cells for adoptive immunotherapy and can be used to generate universal off-the-shelf CAR T cells that are readily available for administration into patients as required. Genome editing tools such as TALENs and CRISPR-Cas9 and non-gene editing methods such as short hairpin RNA and blockade of protein expression are currently used to enhance CAR T cell safety and efficacy by abrogating non-specific toxicity in the form of graft versus host disease (GVHD) and preventing CAR T cell rejection by the host.
ISSN:2050-7771
2050-7771
DOI:10.1186/s40364-022-00359-3